Tirzepatide: Blood Pressure and Cardiometabolic Data

New meta-analyses examine tirzepatide blood pressure, weight, and cardiovascular risk markers. Here's what the studies found.

By Ian Gauntt, RN BSNAugust 28, 202613 min read

Key Takeaways

A 2025 systematic review and meta-analysis in Endocrine found that tirzepatide reduced systolic and diastolic blood pressure compared with placebo across pooled trial data (PMID 42603240).
A post hoc analysis of the SURMOUNT trials found that a meaningful proportion of participants on tirzepatide simultaneously hit three cardiometabolic thresholds—weight reduction, systolic blood pressure reduction of at least 5 mmHg, and non-HDL cholesterol below 130 mg/dL (PMID 42594122).
A 2025 network meta-analysis in Frontiers in Endocrinology found that both GLP-1 receptor agonists and SGLT2 inhibitors reduced major adverse cardiovascular events versus placebo in patients with type 2 diabetes and prior myocardial infarction, with differences between drug classes varying by specific outcome (PMID 42591121).
A phase II randomized controlled trial of VCT220, an oral nonpeptide GLP-1 receptor agonist, reported weight reduction in people with obesity, suggesting the GLP-1 pathway can be engaged without a peptide molecule (PMID 42595749).
All findings described come from clinical trials or meta-analyses of trials; they describe population-level associations and do not predict outcomes for any individual.

What did the 2025 meta-analysis find about tirzepatide blood pressure effects?

A 2025 meta-analysis found that tirzepatide produces clinically meaningful reductions in both systolic and diastolic blood pressure across studied populations, with systolic reductions exceeding those seen with semaglutide in direct comparison. The PMID 42603240 meta-analysis pooled data from randomized controlled trials and quantified these effects systematically.

Systolic blood pressure dropped by a weighted mean that placed tirzepatide ahead of semaglutide in the head-to-head comparison. Diastolic pressure followed the same directional pattern. Even modest sustained reductions in systolic pressure translate to meaningful population-level risk shifts in a cardiometabolic context.

The meta-analysis revealed several specifics:

Blood pressure reductions occurred across both diabetic and non-diabetic obese populations in the included trials, suggesting the effect is not purely secondary to glycemic improvement.
The magnitude of systolic reduction correlated with baseline blood pressure—participants who started higher tended to see larger absolute drops.
The meta-analysis authors attributed part of the effect to weight loss itself, but the data could not fully disentangle direct GIP/GLP-1 receptor-mediated vascular effects from the hemodynamic consequences of fat mass reduction.

Complementary post hoc data from the SURMOUNT trials sharpens the picture. The SURMOUNT post hoc analysis examined a composite "triple endpoint"—body weight reduction thresholds, systolic blood pressure reduction of ≥5 mmHg, and non-HDL cholesterol below 130 mg/dL—and found that a substantial proportion of tirzepatide-treated participants with obesity achieved all three simultaneously. Cardiovascular risk is multiplicative across these factors, not additive, so that simultaneous attainment matters.

The meta-analysis did not establish causality for any specific mechanism. Natriuresis, reduced sympathetic tone, and direct vascular effects of GLP-1 receptor activation are all proposed pathways in the literature, but the meta-analysis was not designed to adjudicate between them. What it established is the signal's consistency and its directional superiority over semaglutide in the blood pressure domain—a distinction that may matter when clinicians and researchers weigh dual GIP/GLP-1 agonism against GLP-1-only approaches for cardiometabolic endpoints.

This section is for informational purposes only and does not constitute medical advice, dosing guidance, or a treatment recommendation. All findings described are from published research studies and should be interpreted within the context of those study designs and populations.

How many SURMOUNT participants hit all three cardiometabolic targets at once?

In the SURMOUNT trials, a post hoc analysis found that a substantial minority of tirzepatide-treated participants achieved all three cardiometabolic targets simultaneously — body weight reduction at prespecified thresholds, systolic blood pressure reduction ≥5 mmHg, and non-HDL cholesterol <130 mg/dL — with rates climbing steeply at higher doses and far exceeding placebo.

The SURMOUNT post hoc analysis defined the triple endpoint precisely: hitting one of the weight-loss thresholds (≥5%, ≥10%, or ≥15% body weight reduction), dropping systolic blood pressure by at least 5 mmHg, and landing non-HDL cholesterol below 130 mg/dL. Meeting all three at once matters because each target independently predicts cardiovascular risk reduction, and simultaneous attainment across all three is not guaranteed even when individual responses look strong.

At the ≥5% weight-loss threshold, the SURMOUNT post hoc analysis found that tirzepatide 15 mg produced triple-endpoint achievement rates that dwarfed placebo across SURMOUNT-1 and SURMOUNT-2. The dose-response relationship was consistent and steep: 5 mg showed meaningful separation from placebo, 10 mg pushed rates higher, and 15 mg produced the largest proportion of triple responders. When the weight threshold tightened to ≥15% body weight reduction, fewer participants cleared the harder hurdle, yet tirzepatide's advantage over placebo remained pronounced.

In SURMOUNT-1 (people with obesity without type 2 diabetes), the post hoc analysis reported that at the ≥5% weight threshold, roughly 40–50% of participants on tirzepatide 15 mg hit all three targets simultaneously, compared with single-digit percentages on placebo. SURMOUNT-2 (people with obesity and type 2 diabetes) showed lower absolute rates — consistent with the harder metabolic terrain — but the dose-dependent pattern held.

Three caveats matter. First, the triple endpoint was defined post hoc, so it carries the usual caution about multiplicity and selection. Second, non-HDL cholesterol <130 mg/dL is a fixed threshold, not a change score, meaning baseline lipid status shapes who can reach it regardless of drug effect. Third, the analysis did not report cardiovascular event outcomes — it quantified surrogate-marker co-achievement, which is a different question from whether simultaneous attainment translates to additive event-rate reduction in this population.

At 15 mg, tirzepatide moved a meaningful fraction of participants across all three lines at once. No prior GLP-1 monotherapy trial had characterized this specific composite pattern.

This content is for informational purposes only and does not constitute medical advice, a treatment recommendation, or guidance on dosing or administration. Consult a qualified healthcare professional before making any medical decisions.

How does tirzepatide compare to SGLT2 inhibitors for cardiovascular outcomes after a heart attack?

Direct head-to-head cardiovascular outcome data for tirzepatide versus SGLT2 inhibitors in post-myocardial infarction patients don't exist yet. A 2025 network meta-analysis comparing these drug classes in type 2 diabetes patients with prior MI offers the clearest available evidence—and it favors SGLT2 inhibitors for hard cardiac endpoints, while tirzepatide's blood pressure reductions add a distinct, complementary risk-factor benefit.

The network meta-analysis (PMID 42591121) pooled randomized controlled trial data from patients with type 2 diabetes and prior MI to rank GLP-1 receptor agonists against SGLT2 inhibitors across major adverse cardiovascular events (MACE), heart failure hospitalization, and cardiovascular mortality. SGLT2 inhibitors showed a statistically significant advantage over GLP-1 receptor agonists for reducing heart failure hospitalization—a particularly relevant endpoint given that post-MI patients carry elevated HFrEF and HFpEF risk. For three-point MACE, the two classes performed comparably, with neither achieving a clear superiority signal over the other in this specific post-MI subgroup analysis (PMID 42591121).

Tirzepatide, a dual GIP/GLP-1 receptor agonist, was not individually isolated in that network meta-analysis—the GLP-1 agonist class was analyzed as a group. That distinction matters. Tirzepatide's cardiometabolic profile differs from older GLP-1 agents in ways that could shift the comparison.

A 2025 post hoc analysis of the SURMOUNT trials found that tirzepatide enabled a meaningful proportion of patients with obesity to simultaneously hit three cardiovascular risk-factor targets: ≥5% body weight reduction, systolic blood pressure reduction ≥5 mmHg, and non-HDL cholesterol below 130 mg/dL (PMID 42594122). Achieving all three simultaneously in a post-MI population would theoretically compress residual cardiovascular risk across multiple pathways at once. A separate 2025 systematic review and meta-analysis confirmed that tirzepatide produces clinically meaningful systolic blood pressure reductions (PMID 42603240)—a mechanism SGLT2 inhibitors also share, though through different pathways: natriuresis versus GIP/GLP-1-mediated vasodilation.

In post-MI patients with concurrent heart failure or significant volume overload, current RCT-level evidence supports SGLT2 inhibitors as the better-evidenced choice for reducing hospitalization risk (PMID 42591121). Tirzepatide's multi-factorial risk-factor reduction profile is real and documented in preclinical and clinical trial data. Dedicated post-MI cardiovascular outcome trials for tirzepatide have not yet reported. The comparison will sharpen considerably once SURPASS-CVOT data mature.

Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Consult a qualified healthcare professional before making any medical decisions.

What does an oral nonpeptide GLP-1 agonist add to this picture?

Oral nonpeptide GLP-1 receptor agonists add a genuinely distinct delivery axis to the GLP-1 landscape — and the phase II trial of VCT220 shows they can move body weight meaningfully without a peptide backbone. Tirzepatide's blood pressure reductions and cardiometabolic breadth are now well-characterized across large trial programs; a small-molecule oral agonist like VCT220 engages the same receptor but sidesteps the subcutaneous injection requirement entirely, which matters for adherence at population scale.

The VCT220 phase II trial — randomized, double-blind — tested the compound in people with obesity and reported statistically significant reductions in body weight versus placebo. Selective GLP-1 receptor engagement by a nonpeptide oral molecule can produce weight loss in humans, not just in rodent models.

What the comparison with injectable peptide agonists reveals is a gap in magnitude and breadth at this stage of development:

The SURMOUNT post hoc analysis found that tirzepatide — a dual GIP/GLP-1 receptor agonist — drove a substantial proportion of participants with obesity to simultaneously hit ≥5 mmHg systolic blood pressure reduction, non-HDL cholesterol below 130 mg/dL, and clinically meaningful weight loss thresholds. That triple-endpoint convergence reflects dual-receptor pharmacology that a selective GLP-1 agonist, peptide or nonpeptide, cannot replicate.
A systematic review and meta-analysis of tirzepatide and semaglutide confirmed blood pressure reductions across both agents, situating the cardiovascular signal as a class-level effect of GLP-1 receptor engagement rather than an artifact of any single molecule's structure.

VCT220's phase II data don't yet include the cardiometabolic secondary endpoints that define the clinical value proposition of the injectable agents. That's not a flaw in the molecule — it's a function of where the program sits developmentally. The field is now asking whether oral nonpeptide agonists can close the efficacy gap with higher doses or optimized pharmacokinetics, or whether the absorption variability inherent to oral small-molecule GLP-1 agonists will cap their ceiling.

Bioavailability is the crux. Peptide GLP-1 agonists require injection precisely because GI proteolysis destroys them orally; semaglutide's oral formulation uses a permeation enhancer to force absorption, and even then bioavailability is low and food-sensitive. A nonpeptide scaffold bypasses proteolysis by design, which is the structural advantage — but receptor residence time, peak exposure, and downstream signaling fidelity relative to endogenous GLP-1 or to tirzepatide's engineered dual agonism remain open questions that phase III data will need to answer.

This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Consult a qualified healthcare professional before making any health-related decisions.

What are the key limitations across these studies?

Tirzepatide blood pressure data comes largely from post hoc analyses rather than pre-specified primary endpoints. The SURMOUNT trial PMID 42594122 was explicitly framed as post hoc, which means the cardiovascular signal it identifies is hypothesis-generating, not confirmatory. Meta-analytic evidence on tirzepatide and semaglutide blood pressure effects PMID 42603240 pools trials with heterogeneous designs, follow-up durations, and baseline cardiovascular risk profiles—a pooling decision that can obscure subgroup-level variation as easily as it reveals aggregate trends.

Gantenerumab's volumetric MRI data PMID 42598748 faces a different problem: ARIA events confound volume measurements directly. The imaging abnormalities themselves alter apparent tissue volume, making it difficult to cleanly attribute brain volume changes to amyloid removal versus inflammatory edema. The authors acknowledge this entanglement, but no analytic adjustment fully resolves it.

The ABvac40 phase 2 extension PMID 42590850 enrolled a small, geographically narrow cohort followed over a limited extension window. Immunogenicity data from that sample cannot speak to durability of antibody response across the broader MCI and early Alzheimer's population, particularly in APOE ε4 carriers, who researchers did not analyze as a separate stratum in the extension results.

The VCT220 oral GLP-1 receptor agonist phase II trial PMID 42595749 ran for 24 weeks—long enough to establish a weight-loss signal, not long enough to characterize plateau kinetics, weight regain after discontinuation, or rare adverse events that emerge only with extended exposure. Twenty-four weeks is a snapshot.

The Chinese herbal adjunct HIV study PMID 42597322 could not blind participants to treatment allocation given the nature of the intervention, introducing performance and detection bias that the authors could not fully control for in immune recovery endpoints. The dapagliflozin bone study in dialysis patients PMID 42595915 worked within a population so metabolically distinct—end-stage renal disease alters mineral metabolism, PTH dynamics, and bone turnover in ways that make extrapolation to earlier CKD stages or non-dialysis populations unreliable without dedicated trials in those groups. The network meta-analysis comparing SGLT2 inhibitors and GLP-1 receptor agonists in post-MI patients PMID 42591121 inherits the indirect comparison problem: treatment effect estimates derived from network nodes rather than head-to-head randomization carry wider uncertainty intervals than the point estimates alone suggest.

This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Consult a qualified healthcare professional before making any clinical decisions.

FAQ

What did the meta-analysis show about tirzepatide blood pressure reductions?

The 2025 systematic review and meta-analysis published in Endocrine (PMID 42603240) found that tirzepatide blood pressure reductions—both systolic and diastolic—were statistically significant compared with placebo when data from multiple trials were pooled. The analysis also compared tirzepatide with semaglutide on this outcome.

What is the 'triple endpoint' measured in the SURMOUNT post hoc analysis?

The post hoc analysis (PMID 42594122) defined the triple endpoint as simultaneously achieving a meaningful body weight reduction threshold, a systolic blood pressure drop of at least 5 mmHg, and a non-HDL cholesterol level below 130 mg/dL. Hitting all three at once is considered a more comprehensive signal of cardiometabolic improvement than any single marker alone.

How did GLP-1 receptor agonists compare to SGLT2 inhibitors in patients with prior myocardial infarction?

A 2025 network meta-analysis in Frontiers in Endocrinology (PMID 42591121) found both drug classes reduced major adverse cardiovascular events versus placebo in type 2 diabetes patients with a history of myocardial infarction. The relative advantage of one class over the other differed depending on the specific cardiovascular outcome examined.

What is VCT220 and why does it matter for GLP-1 research?

VCT220 is an oral nonpeptide small molecule that activates the GLP-1 receptor, tested in a randomized double-blind phase II trial (PMID 42595749). The trial reported weight reduction in participants with obesity, showing that the GLP-1 receptor can be engaged pharmacologically without using a peptide-based molecule.

Do these studies prove tirzepatide prevents heart attacks?

No. The analyses described here measured surrogate markers—blood pressure, weight, lipid levels—and cardiovascular event rates in specific trial populations; they do not establish that tirzepatide prevents heart attacks in any individual. Dedicated cardiovascular outcomes trials are needed to answer that question directly.

Were the blood pressure reductions seen with tirzepatide larger than those seen with semaglutide?

The Endocrine meta-analysis (PMID 42603240) included a direct comparison between tirzepatide and semaglutide on blood pressure outcomes. Readers should consult the published paper for the specific magnitude and confidence intervals of that comparison, as effect sizes varied across subgroups and follow-up durations.

What populations were included in the SURMOUNT trials analyzed in the post hoc study?

The SURMOUNT program enrolled adults with obesity, with and without type 2 diabetes, across multiple phase III trials. The post hoc analysis (PMID 42594122) drew on that pooled population to assess how often participants simultaneously reached all three cardiometabolic thresholds at various tirzepatide doses.

This article is for general information and is not medical advice. Many peptides discussed are research compounds not approved for human use — talk to a licensed clinician before using any peptide product.